Literature DB >> 7546904

Preparation and characterization of human HIV type 1 neutralizing reference sera.

L K Vujcic1, G V Quinnan.   

Abstract

Reference neutralizing antibody (NA) reagents are needed for laboratories to be able to compare results of neutralization assays that will be used to monitor HIV-1 vaccine recipients. In an effort to establish such reference reagents two asymptomatic, seropositive patients were identified with medium to high amounts of cross-reactive NA activity against a number of HIV-1 strains. Sera obtained from each individual at three or four sequential phlebotomies were pooled, and the two pools were each distributed in > 3000 aliquots into glass ampoules and lyophilized, and the ampoules were flame sealed. An HIV-1 antibody-negative reference serum was prepared in a similar fashion after pooling serum from four individuals. Ampoules were tested for uniformity of fill, sterility, moisture content, residual oxygen, stability, infectivity, and presence of antibody. An international collaborative study was conducted to determine the potency of the samples in six laboratories, each using their own neutralization assays and reagents. The results indicated reasonable consistency between laboratories and that both sera have sufficient titers against a variety of strains for use as reference reagents. These reference sera have been included in the World Health Organization (WHO) AIDS Reagent Project and are available through the three AIDS reagent repositories.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546904     DOI: 10.1089/aid.1995.11.783

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  39 in total

1.  Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.

Authors:  Chih-chin Huang; Miro Venturi; Shahzad Majeed; Michael J Moore; Sanjay Phogat; Mei-Yun Zhang; Dimiter S Dimitrov; Wayne A Hendrickson; James Robinson; Joseph Sodroski; Richard Wyatt; Hyeryun Choe; Michael Farzan; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-23       Impact factor: 11.205

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.

Authors:  M Gordon Joyce; Masaru Kanekiyo; Ling Xu; Christian Biertümpfel; Jeffrey C Boyington; Stephanie Moquin; Wei Shi; Xueling Wu; Yongping Yang; Zhi-Yong Yang; Baoshan Zhang; Anqi Zheng; Tongqing Zhou; Jiang Zhu; John R Mascola; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

6.  Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Authors:  Maria Leavitt; Eun Ju Park; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

7.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 8.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Authors:  Josh D Nelson; Florence M Brunel; Richard Jensen; Emma T Crooks; Rosa M F Cardoso; Meng Wang; Ann Hessell; Ian A Wilson; James M Binley; Philip E Dawson; Dennis R Burton; Michael B Zwick
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

10.  Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12.

Authors:  Rebecca L Dunfee; Elaine R Thomas; Dana Gabuzda
Journal:  Retrovirology       Date:  2009-07-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.